Good Life Advisors LLC Purchases New Stake in Metagenomi, Inc. (NASDAQ:MGX)

Good Life Advisors LLC purchased a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 125,000 shares of the company’s stock, valued at approximately $451,000.

A number of other large investors have also added to or reduced their stakes in MGX. BNP Paribas Financial Markets lifted its holdings in Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares during the period. Verition Fund Management LLC bought a new position in shares of Metagenomi during the third quarter valued at approximately $82,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Metagenomi by 209.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock valued at $296,000 after acquiring an additional 92,468 shares in the last quarter. Geode Capital Management LLC lifted its stake in Metagenomi by 105.8% in the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after acquiring an additional 173,796 shares during the period. Finally, Virtu Financial LLC bought a new stake in Metagenomi in the third quarter valued at $33,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MGX shares. HC Wainwright raised their target price on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.67.

Metagenomi Price Performance

Shares of Metagenomi stock opened at $2.44 on Friday. Metagenomi, Inc. has a 12 month low of $1.61 and a 12 month high of $12.50. The business has a fifty day simple moving average of $3.03 and a two-hundred day simple moving average of $2.66.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.